Timothy J. Richmond - 01 Mar 2024 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
EVP, CHIEF HR OFFICER
Signature
T.O. Odutayo, attorney-in-fact for Timothy J. Richmond
Issuer symbol
ABBV
Transactions as of
01 Mar 2024
Net transactions value
-$13,415,503
Form type
4
Filing time
05 Mar 2024, 17:30:50 UTC
Previous filing
01 Mar 2024
Next filing
18 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common stock, $0.01 par value Options Exercise $2,804,152 +45,700 +104% $61.36 89,517 01 Mar 2024 Direct
transaction ABBV Common stock, $0.01 par value Sale $2,718,677 -15,412 -17% $176.40 74,105 01 Mar 2024 Direct F1, F2
transaction ABBV Common stock, $0.01 par value Sale $5,382,480 -30,288 -41% $177.71 43,817 01 Mar 2024 Direct F1, F3
transaction ABBV Common stock, $0.01 par value Sale $1,737,577 -9,853 -22% $176.35 33,964 01 Mar 2024 Direct F1, F4
transaction ABBV Common stock, $0.01 par value Sale $3,576,769 -20,127 -59% $177.71 13,837 01 Mar 2024 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right to buy) Options Exercise $2,804,152 -45,700 -100% $61.36 0 01 Mar 2024 Common Stock 45,700 $61.36 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 13, 2023.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.76 to $176.72, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 he price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.77 to $177.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.76 to $176.69, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.72 to $177.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.